{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:01:41Z","timestamp":1788379301987,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":131,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.vaccine.2024.04.027","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T12:52:23Z","timestamp":1712839943000},"page":"3321-3332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6534-0506","authenticated-orcid":false,"given":"Susan","family":"Ahern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Browne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conor","family":"Teljeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e1ir\u00edn","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2024.04.027_b0005","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14760584.2017.1394843","article-title":"Varicella and herpes zoster vaccine development: lessons learned","volume":"16","author":"Warren-Gash","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.04.027_b0010","unstructured":"European Centre for Disease Prevention and Control. Factsheet about varicella. Fr\u00f6sunda, Sweden. ECDC; 2021. [Available from: https:\/\/www.ecdc.europa.eu\/en\/varicella\/facts [Accessed 13 March 2024]."},{"issue":"13","key":"10.1016\/j.vaccine.2024.04.027_b0015","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1017\/S0950268817001546","article-title":"A systematic review of varicella seroprevalence in european countries before universal childhood immunization: deriving incidence from seroprevalence data","volume":"145","author":"Bollaerts","year":"2017","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.027_b0020","doi-asserted-by":"crossref","first-page":"e2407","DOI":"10.1002\/rmv.2407","article-title":"Clinical efficacy and effectiveness of alternative varicella vaccination strategies: an overview of reviews","volume":"33","author":"Ahern","year":"2023","journal-title":"Rev Med Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2024.04.027_b0025","doi-asserted-by":"crossref","first-page":"e2416","DOI":"10.1002\/rmv.2416","article-title":"Safety of varicella vaccination strategies: an overview of reviews","volume":"33","author":"Ahern","year":"2023","journal-title":"Rev Med Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2024.04.027_b0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/14760584.2017.1294069","article-title":"Severe varicella in persons vaccinated with varicella vaccine (breakthrough varicella): a systematic literature review","volume":"16","author":"Leung","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.04.027_b0035","article-title":"Changing epidemiology of varicella outbreaks in the United States during the varicella vaccination program, 1995\u20132019","volume":"226(Supplement_4):S400\u2013S6","author":"Leung","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2024.04.027_b0040","unstructured":"European Centre for Disease Prevention and Control. ECDC Guidance. Varicella vaccination in the European Union. Fr\u00f6sunda, Sweden: ECDC; 2015."},{"issue":"3","key":"10.1016\/j.vaccine.2024.04.027_b0045","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2018.1546525","article-title":"Global impact of varicella vaccination programs","volume":"15","author":"Varela","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.04.027_b0050","unstructured":"World Health Organization. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Geneva, Switzlerand; 2014. Contract No.: 25."},{"key":"10.1016\/j.vaccine.2024.04.027_b0055","series-title":"Immunisation Guidelines. Chapter 23 Varicella-Zoster","author":"Health Service Executive","year":"2022"},{"key":"10.1016\/j.vaccine.2024.04.027_b0060","unstructured":"Central Statistics Office. Vital Statistics Yearly Summary 2021. CSO; 2022. [Available from: https:\/\/www.cso.ie\/en\/releasesandpublications\/ep\/p-vsys\/vitalstatisticsyearlysummary2021\/ Accessed 13 March 2024]."},{"issue":"7","key":"10.1016\/j.vaccine.2024.04.027_b0065","article-title":"Varicella related hospital admissions in Ireland","volume":"112","author":"McCarthy","year":"2019","journal-title":"Ir Med J"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.027_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-021-12343-x","article-title":"Economic burden of varicella in Europe in the absence of universal varicella vaccination","volume":"21","author":"Pawaskar","year":"2021","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.vaccine.2024.04.027_b0075","doi-asserted-by":"crossref","first-page":"e0282327","DOI":"10.1371\/journal.pone.0282327","article-title":"Systematic review of economic evaluations of varicella vaccination programmes","volume":"18","author":"Anderson","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.027_b0080","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jval.2020.10.004","article-title":"What we know now: an economic evaluation of chickenpox vaccination and dose timing using an agent-based model","volume":"24","author":"Rafferty","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2024.04.027_b0085","unstructured":"European Centre for Disease Prevention and Control. Vaccine Scheduler. Varicella: Recommended vaccinations. Fr\u00f6sunda, Sweden. ECDC; 2021. [Available from: https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=11&SelectedCountryIdByDisease=-1 Accessed 13 March 2024]."},{"key":"10.1016\/j.vaccine.2024.04.027_b0090","unstructured":"Australian Government. Department of Health. Australian Immunisation Handbook. Varicella (chickenpox). Canberra, Australia. Commonwealth of Australia; 2021. [updated 23 April 2019. Available from: https:\/\/immunisationhandbook.health.gov.au\/vaccine-preventable-diseases\/varicella-chickenpox Accessed 13 March 2024]."},{"key":"10.1016\/j.vaccine.2024.04.027_b0095","unstructured":"Health New Zealand - Te Whatu Ora. Immunisation Handbook 2024. Chapter 22. Varicella (chickenpox). Wellington, New Zealand. Te Kawanatanga o Aotearoa - New Zealand Government; 2024. [Available from: https:\/\/www.tewhatuora.govt.nz\/for-the-health-sector\/vaccine-information\/immunisation-handbook-2024-version-1\/ Accessed 13 March 2024]."},{"issue":"7","key":"10.1016\/j.vaccine.2024.04.027_b0100","doi-asserted-by":"crossref","first-page":"e0254080","DOI":"10.1371\/journal.pone.0254080","article-title":"Clinical and economic impact of universal varicella vaccination in Norway: a modeling study","volume":"16","author":"Pawaskar","year":"2021","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.vaccine.2024.04.027_b0105","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.ebiom.2015.08.017","article-title":"Distribution of health effects and cost-effectiveness of varicella vaccination are shaped by the impact on herpes zoster","volume":"2","author":"van Lier","year":"2015","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.vaccine.2024.04.027_b0110","doi-asserted-by":"crossref","first-page":"2045152","DOI":"10.1080\/21645515.2022.2045152","article-title":"Cost effectiveness and budget impact of universal varicella vaccination in Russia","volume":"18","author":"Marijam","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2024.04.027_b0115","doi-asserted-by":"crossref","first-page":"e0251644","DOI":"10.1371\/journal.pone.0251644","article-title":"Cost-effectiveness of varicella and herpes zoster vaccination in Sweden: an economic evaluation using a dynamic transmission model","volume":"16","author":"Wolff","year":"2021","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.vaccine.2024.04.027_b0120","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1097\/INF.0000000000003136","article-title":"Health impact and cost-effectiveness assessment for the introduction of universal Varicella vaccination in Switzerland","volume":"40","author":"Heininger","year":"2021","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"10.1016\/j.vaccine.2024.04.027_b0125","doi-asserted-by":"crossref","first-page":"e3617","DOI":"10.1093\/cid\/ciaa1708","article-title":"Epidemiological impact and cost-effectiveness of Varicella vaccination strategies in the United Kingdom","volume":"73","author":"Akpo","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.04.027_b0130","series-title":"Guidelines for the economic evaluation of health Technologies in Ireland","author":"Health Information and Quality Authority","year":"2020"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.027_b0135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jval.2020.09.005","article-title":"Economic evaluation of vaccines: belgian reflections on the need for a broader perspective","volume":"24","author":"Annemans","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2024.04.027_b0140","unstructured":"Health Protection Surveillance Centre. Herpes zoster (shingles) notifications from sentinel general practice surveillance programme. 2022."},{"issue":"45","key":"10.1016\/j.vaccine.2024.04.027_b0145","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1016\/j.vaccine.2007.07.036","article-title":"The comparative sero-epidemiology of varicella zoster virus in 11 countries in the european region","volume":"25","author":"Nardone","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.04.027_b0150","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1371\/journal.pmed.0050074","article-title":"Social contacts and mixing patterns relevant to the spread of infectious diseases","volume":"5","author":"Mossong","year":"2008","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2024.04.027_b0155","year":"2019","journal-title":"CDC"},{"issue":"9","key":"10.1016\/j.vaccine.2024.04.027_b0160","doi-asserted-by":"crossref","first-page":"e3210","DOI":"10.1093\/cid\/ciaa1185","article-title":"Herpes zoster and postherpetic neuralgia: changing incidence rates from 1994 to 2018 in the United States","volume":"73","author":"Thompson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2024.04.027_b0165","doi-asserted-by":"crossref","first-page":"e004833","DOI":"10.1136\/bmjopen-2014-004833","article-title":"Systematic review of incidence and complications of herpes zoster: towards a global perspective","volume":"4","author":"Kawai","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2024.04.027_b0170","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10096-017-3153-y","article-title":"Acute herpes zoster and post herpetic neuralgia in primary care: a study of diagnosis, treatment and cost","volume":"37","author":"Crosbie","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2024.04.027_b0175","unstructured":"World Health Organization. INFORMATION SHEET - OBSERVED RATE OF VACCINE REACTIONS VARICELLA ZOSTER VIRUS VACCINE. WHO; 2012. [Available from: https:\/\/cdn.who.int\/media\/docs\/default-source\/pvg\/global-vaccine-safety\/varicella-zoster-vaccine-rates-information-sheet.pdf?sfvrsn=14f90c6_4&download=true Accessed 13 March 2024]."},{"issue":"10","key":"10.1016\/j.vaccine.2024.04.027_b0180","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/adc.88.10.862","article-title":"Varicella vaccination in England and Wales: cost-utility analysis","volume":"88","author":"Brisson","year":"2003","journal-title":"Arch Dis Child"},{"issue":"49","key":"10.1016\/j.vaccine.2024.04.027_b0185","doi-asserted-by":"crossref","first-page":"8326","DOI":"10.1016\/j.vaccine.2007.09.066","article-title":"Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"25","author":"Pellissier","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.04.027_b0190","series-title":"Health technology assessment (HTA) of extending the national immunisation schedule to include HPV vaccination of boys","author":"Health Information and Quality Authority","year":"2018"},{"key":"10.1016\/j.vaccine.2024.04.027_b0195","unstructured":"S.I. No. 577\/2016 - Health Professionals (Payments to General Practitioners) (National Immunisation Programmes) Regulations 2016., Stat. S.I. No. 577\/2016 (2016)."},{"key":"10.1016\/j.vaccine.2024.04.027_b0200","series-title":"Driving change in immunisation - the role of the National Immunisation Office 2005\u20132011","author":"Health Service Executive","year":"2012"},{"issue":"19","key":"10.1016\/j.vaccine.2024.04.027_b0205","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.vaccine.2021.03.085","article-title":"Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: results from five east european countries","volume":"39","author":"Prymula","year":"2021","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.027_b0210","doi-asserted-by":"crossref","first-page":"1959148","DOI":"10.1080\/21645515.2021.1959148","article-title":"A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in russian children","volume":"18","author":"Namazova-Baranova","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2024.04.027_b0215","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/CEOR.S229685","article-title":"The cost-effectiveness of universal varicella vaccination in Italy: a model-based assessment of vaccination strategies","volume":"12","author":"Azzari","year":"2020","journal-title":"ClinicoEconomics and outcomes research: CEOR"},{"issue":"46","key":"10.1016\/j.vaccine.2024.04.027_b0220","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.1016\/j.vaccine.2018.09.013","article-title":"Herpes zoster in the context of varicella vaccination\u2013an equation with several variables","volume":"36","author":"Wutzler","year":"2018","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2024.04.027_b0225","doi-asserted-by":"crossref","first-page":"e66485","DOI":"10.1371\/journal.pone.0066485","article-title":"Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review","volume":"8","author":"Ogunjimi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2024.04.027_b0230","article-title":"Towards a broader assessment of value in vaccines: the BRAVE way forward","volume":"1\u201313","author":"Bell","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.vaccine.2024.04.027_b0235","unstructured":"Centers for Disease Control and Prevention. Complications of Shingles. CDC; 2019. [updated 1 July 2019. Available from: https:\/\/www.cdc.gov\/shingles\/about\/complications.html Accessed 15 March 2023]."},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.027_b0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.16","article-title":"Varicella zoster virus infection","volume":"1","author":"Gershon","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.vaccine.2024.04.027_b0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-015-1753-y","article-title":"Herpes zoster-associated mortality in Europe: a systematic review","volume":"15","author":"Bricout","year":"2015","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.vaccine.2024.04.027_b0250","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1017\/S0950268800004714","article-title":"Modelling the impact of immunization on the epidemiology of varicella zoster virus","volume":"125","author":"Brisson","year":"2000","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2024.04.027_b0255","doi-asserted-by":"crossref","unstructured":"Poletti P, Melegaro A, Ajelli M, Del Fava E, Guzzetta G, Faustini L, et al. Perspectives on the impact of varicella immunization on herpes zoster. A model-based evaluation from three European countries. PloS one. 2013;8(4):e60732.","DOI":"10.1371\/journal.pone.0060732"},{"key":"10.1016\/j.vaccine.2024.04.027_b0260","unstructured":"Health Protection Surveillance Centre. Immunisation uptake statistics at 12 and 24 months of age Dublin. HPSC; 2022. [Available from: https:\/\/www.hpsc.ie\/a-z\/vaccinepreventable\/vaccination\/immunisationuptakestatistics\/immunisationuptakestatisticsat12and24monthsofage\/quarterlyreports\/2022\/ Accessed 13 March 2024]."},{"key":"10.1016\/j.vaccine.2024.04.027_b0265","unstructured":"Health Protection Surveillance Centre. Immunisation uptake statistics for Junior Infants (2020-2021) Dublin. HPSC; 2022. [Available from: https:\/\/www.hpsc.ie\/a-z\/vaccinepreventable\/vaccination\/immunisationuptakestatistics\/immunisationuptakestatisticsforjuniorinfants\/Jr.%20Infants%20DTaP-IPV%20&%20MMR%202020-2021-Table%20V2.0.pdf Accessed 13 March 2024]."},{"issue":"1","key":"10.1016\/j.vaccine.2024.04.027_b0270","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/21645515.2015.1093263","article-title":"Primary vaccine failure to routine vaccines: why and what to do?","volume":"12","author":"Wiedermann","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"13","key":"10.1016\/j.vaccine.2024.04.027_b0275","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.vaccine.2011.01.037","article-title":"Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England","volume":"29","author":"Van Hoek","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.04.027_b0280","unstructured":"Healthcare Pricing Office. Hospital Inpatient Enquiry (HIPE) system discharge data (2015-2019) 2023."},{"key":"10.1016\/j.vaccine.2024.04.027_b0285","unstructured":"Healthcare Pricing Office. Activity Based Funding Admitted Patient Price List Dublin. HPO; 2022. [Available from: https:\/\/www.hpo.ie\/abf\/ABF2022AdmittedPatientPriceList.pdf Accessed 13 March 2024]."},{"key":"10.1016\/j.vaccine.2024.04.027_b0290","unstructured":"Central Statistics Office. Earnings Analysis using Administrative Data Sources 2018. CSO; 2022. [Available from: https:\/\/www.cso.ie\/en\/releasesandpublications\/ep\/p-eaads\/earningsanalysisusingadministrativedatasources2018\/age\/#:\u223c:text=The%20age%20group%20with%20the%20highest%20median%20weekly,the%2015-24%20year%20olds%20at%20%E2%82%AC294.15%20in%202018 Accessed 8 March 2024]."},{"key":"10.1016\/j.vaccine.2024.04.027_b0295","article-title":"Unit costs for non-acute care in Ireland 2016\u20132019. HRB open","volume":"4","author":"Smith","year":"2021","journal-title":"Research"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24004419?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24004419?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T15:30:22Z","timestamp":1729611022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24004419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":59,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0264410X24004419"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.027","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An economic evaluation and incremental analysis of the cost effectiveness of three universal childhood varicella vaccination strategies for Ireland","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.04.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}